Probiotix Health (FRA:X90) Debt-to-EBITDA : 0.00 (As of Jun. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Probiotix Health Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Probiotix Health's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €0.00 Mil. Probiotix Health's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €0.00 Mil. Probiotix Health's annualized EBITDA for the quarter that ended in Jun. 2023 was €-1.13 Mil. Probiotix Health's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Probiotix Health's Debt-to-EBITDA or its related term are showing as below:

During the past 4 years, the highest Debt-to-EBITDA Ratio of Probiotix Health was 11.66. The lowest was -2.21. And the median was 4.73.

FRA:X90's Debt-to-EBITDA is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.36
* Ranked among companies with meaningful Debt-to-EBITDA only.

Probiotix Health Debt-to-EBITDA Historical Data

The historical data trend for Probiotix Health's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Probiotix Health Debt-to-EBITDA Chart

Probiotix Health Annual Data

Trend

Dec18

Dec19

Dec20

Dec22

Debt-to-EBITDA

N/A

-2.21

11.70

N/A

Probiotix Health Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Jun22	Dec22	Jun23
Debt-to-EBITDA	Get a 7-Day Free Trial			2.78	-	-	N/A	-

Competitive Comparison of Probiotix Health's Debt-to-EBITDA

For the Biotechnology subindustry, Probiotix Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Probiotix Health's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Probiotix Health's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Probiotix Health's Debt-to-EBITDA falls into.

Probiotix Health Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Probiotix Health's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	0)	/	N/A
	=	N/A

Probiotix Health's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	0)	/	-1.128
	=	0.00

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2023) EBITDA data.

Probiotix Health (FRA:X90) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Probiotix Health Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Probiotix Health's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Probiotix Health (FRA:X90) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Probiotix Health PLC (FRA:X90) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

PBX:UK X90:Germany

Address

Nostell Business Estate, First Floor Zucchi Suite, Wakefield, GBR, WF4 1AB

Website

https://www.probiotixhealth-ir.com

Probiotix Health PLC develops probiotics to tackle cardiovascular disease and other lifestyle conditions which are affecting growing numbers of people across the world. The Company has one class of business, in three geographical areas being that of identifying and developing microbial strains, compounds and formulations for use in the nutraceutical industry.

Probiotix Health (FRA:X90) Headlines

No Headlines